AI
TNGX icon

Allostery Investments’s Tango Therapeutics TNGX Stock Holding History

Allostery Investments’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,000
Closed -$205K – 18
2025
Q2 		$205K Buy
+40,000
New +$98.9K 2.61% 12

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Allostery Investments's TNGX Position: Q3 2025 in Review

Allostery Investments sold out of Tango Therapeutics (TNGX) in Q3 2025, closing a stake of 40,000 shares — an estimated $205K sold.

Allostery Investments first reported a position in TNGX in Q2 2025 and held it in 1 quarter. The position peaked at $205K in Q2 2025. 141 funds tracked by Wall St. Rank hold TNGX as of Q3 2025.

  • Allostery Investments reported no remaining Tango Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Allostery Investments sold 40,000 Tango Therapeutics shares in Q3 2025, an estimated $205K.
  • Allostery Investments first reported a position in Tango Therapeutics in Q2 2025 and held it in 1 quarter.
  • Allostery Investments's Tango Therapeutics position peaked at $205K in Q2 2025.
  • 141 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2025.

Based on Allostery Investments's 13F filing for Q3 2025.